Ab­b­Vie grabs SHP2 in­hibitors from Chi­na's Ja­co­bio; Chi-Med set on US fil­ing of su­r­u­fa­tinib

→ Ab­b­Vie has found its next tar­get­ed can­cer ther­a­py in Chi­na, li­cens­ing a suite of SHP2 in­hibitors from Bei­jing-based Ja­co­bio. A key node on the RAS/MAP ki­nase path­way, SHP2 helps dri­ve ab­nor­mal cell growth and plays a role in cy­tokine pro­duc­tion as well as im­mune cell re­sponse — which gives two good rea­sons to block it. Ja­co­bio has so far de­vel­oped two ear­ly-stage oral small mol­e­cule can­di­dates, and they will com­plete ear­ly clin­i­cal tri­als on Ab­b­Vie’s tab be­fore hand­ing off to the phar­ma gi­ant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER